BNP/PUT/GILEAD SCIENCES/80/0.1/20.06.25 | Market Closed - Börse Stuttgart 07:18:31 05/07/2024 BST | ||
| 1.41 EUR | +2.17% |
|
| Current month | +11.90% | ||
| 1 month | -10.76% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 05/07/24 | 1.41 | +2.17% |
| 04/07/24 | 1.38 | +7.81% |
| 03/07/24 | 1.28 | 0.00% |
| 02/07/24 | 1.28 | +1.59% |
| 01/07/24 | 1.26 | 0.00% |
Delayed Quote Börse Stuttgart
Last update July 05, 2024 at 07:18 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PC38K1 |
| ISIN | DE000PC38K11 |
| Date issued | 31/01/2024 |
| Strike | 80 $ |
| Maturity | 20/06/2025 (350 Days) |
| Parity | 10 : 1 |
| Emission price | 0.76 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.75 € |
|---|---|
| Lowest since issue | 0.82 € |
| Spread | 0.01 € |
| Spread % | 0.71% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
66.69
USD
Average target price
82.97
USD
Spread / Average Target
+24.41%
- Stock Market
- Warrants
- Warrant
